var data={"title":"Nifedipine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nifedipine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6652?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nifedipine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nifedipine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=nifedipine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Nifedipine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201399\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Adalat CC;</li>\n      <li>Afeditab CR;</li>\n      <li>Nifediac CC [DSC];</li>\n      <li>Nifedical XL [DSC];</li>\n      <li>Procardia;</li>\n      <li>Procardia XL</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201400\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Adalat XL;</li>\n      <li>Nifedipine ER</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201448\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antianginal Agent;</li>\n      <li>\n        Antihypertensive;</li>\n      <li>\n        Calcium Channel Blocker;</li>\n      <li>\n        Calcium Channel Blocker, Dihydropyridine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201404\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Dosage adjustments should occur at 7- to 14-day intervals to allow for adequate assessment of new dose; however, if clinically indicated, titration may be done more rapidly with appropriate monitoring; when switching from immediate-release to sustained-release formulations, use same total daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Chronic stable or vasospastic angina:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Initial: 10 mg 3 times daily; usual dose: 10 to 20 mg 3 times daily; coronary artery spasm may require up to 20 to 30 mg 3 to 4 times daily; single doses &gt;30 mg and total daily doses &gt;120 mg are rarely needed; maximum: 180 mg daily; <b>Note:</b> Do not use for acute anginal episodes; may precipitate myocardial infarction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Initial: 30 or 60 mg once daily; titrate as clinically indicated. Doses &gt;90 mg daily should be used with caution and only if necessary (maximum: 120 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Oral: Extended release: Initial: 30 or 60 mg once daily; usual dosage range (ASH/ISH [Weber 2014]): 30 to 90 mg daily; maximum: 90 to 120 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Achalasia (off-label use):</b> Sublingual: 10 to 30 mg administered 30 to 45 minutes before meals. <b>Note:</b> Clinical response is short acting and use does not provide complete relief of symptoms; consider risks before use (ACG [Vaezi 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension emergency in pregnancy (systolic BP &ge;160 mm Hg or diastolic BP &ge;110 mm Hg) (off-label dose):</b> Oral: Immediate release: 10 mg; may repeat with a 20 mg dose in 20 minutes if needed. Also refer to administration protocols developed by the American College of Obstetricians and Gynecologists (ACOG 692 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>High altitude pulmonary edema (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prevention: ER: 30 mg every 12 hours starting the day before ascent and may be discontinued after staying at the same elevation for 5 days or if descent initiated (WMS [Luks 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment: ER: 30 mg every 12 hours (WMS [Luks 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary hypertension (off-label use):</b> Oral: <b>Note:</b> Guidelines recommend the sustained-release formulation, which is not available in the US; dosing is provided empirically for the ER formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ER: Initial: 60 mg once daily (initiate after demonstrating acute vasoreactivity); may increase cautiously to 120 to 240 mg/day (ESC [Galie 2016]; Taichman 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Raynaud's phenomenon (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Dosage range: 30 to 120 mg once daily (Thompson 2005; Wigley 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: 10 to 30 mg 3 times daily (Thompson 2005; Wigley 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ureteral calculi (distal) (off-label use): </b>Oral: 10 to 30 mg 3 times daily for up to 4 weeks or until expulsion of lower stones (Ye 2011; Zhang 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201425\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=nifedipine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Nifedipine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>High altitude pulmonary edema (off-label use; Pollard, 2001):</b> Oral: <b>Note:</b> Treatment with NIFEdipine is only necessary if response to oxygen and/or descent is unsatisfactory; extended release preparation is preferred, but with proper dose and frequency adjustment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release: 0.5 mg/kg/dose (maximum: 20 mg/dose) every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hypertension (off-label use):</b> Oral: Children 1 to 17 years: Extended release tablet: Initial: 0.2 to 0.5 mg/kg/day once daily or in 2 divided doses; maximum: 3 mg/kg/day up to 120 mg daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201405\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. In the management of hypertension, consider lower initial doses and titrate to response (Aronow 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10293332\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling (has not been studied); the pharmacokinetics of nifedipine are not significantly influenced by the degree of renal impairment (only trace amounts of unchanged drug are found in urine).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Supplemental dose is not necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis effects: Supplemental dose is not necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201406\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling (has not been studied); use with caution. Clearance of nifedipine is reduced in cirrhotic patients, which may lead to increased systemic exposure; monitor closely for adverse effects/toxicity and consider dose adjustments.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201374\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Procardia: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adalat CC: 30 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adalat CC: 30 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adalat CC: 60 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adalat CC: 60 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adalat CC: 90 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adalat CC: 90 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afeditab CR: 30 mg, 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nifediac CC: 30 mg [DSC], 60 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nifedical XL: 30 mg [DSC], 60 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Procardia XL: 30 mg, 60 mg, 90 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 30 mg, 60 mg, 90 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201360\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201378\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: In general, may be administered with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Tablets should be swallowed whole; do not crush, split, or chew. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adalat CC, Afeditab CR, Nifediac CC: Administer on an empty stomach (per manufacturer). Other extended release products may not have this recommendation; consult product labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201377\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of chronic stable or vasospastic angina; treatment of hypertension (ER products only)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Guideline recommendations: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypertension:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The 2014 guideline for the management of high blood pressure in adults (JNC 8) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients (JNC 8 [James, 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; Patients &ge;60 years with systolic blood pressure (SBP) &ge;150 mm Hg or diastolic blood pressure (DBP) &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; Patients &lt;60 years with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; Patients &ge;18 years with diabetes with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&bull; Patients &ge;18 years with chronic kidney disease (CKD) with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic kidney disease (CKD) and hypertension: In patients with chronic kidney disease (CKD), regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general nonblack population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. In the general black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker instead of an ACEI or ARB.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Diabetes and hypertension: The American Diabetes Association (ADA) guidelines suggest that for patients with hypertension and diabetes <i>without</i> albuminuria, any of the 4 classes of blood pressure medications (eg, ACE inhibitors, angiotensin receptor blockers, thiazide-like diuretics, dihydropyridine calcium channel blockers) may be used and have shown beneficial cardiovascular outcomes (ADA 2017a).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469158\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Achalasia; High altitude pulmonary edema (prevention and treatment); Hypertensive emergency in pregnancy; Preterm labor; Pulmonary hypertension; Raynaud phenomenon; Ureteral calculi (distal)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201456\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">NIFEdipine may be confused with niCARdipine, niMODipine, nisoldipine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Procardia XL may be confused with Cartia XT</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Nifedipine (immediate release) is identified as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potential to cause hypotension and risk for precipitating myocardial ischemia (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Nifedipine (immediate release) is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Depin [India] may be confused with Depen brand name for penicillamine [US]; Depon brand name for acetaminophen [Greece]; Dipen brand name for diltiazem [Greece]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nipin [Italy and Singapore] may be confused with Nipent brand name for pentostatin [US, Canada, and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201367\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (10% to 25%; extended release: 3% to 4%), peripheral edema (7% to 30%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (10% to 27%), headache (10% to 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Heartburn (&le;11%), nausea (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Palpitations (&le;7%), transient hypotension (5%), cardiac failure (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Mood changes (&le;7%), nervousness (&le;7%), fatigue (6%), chills (&le;2%), disturbed sleep (&le;2%), equilibrium disturbance (&le;2%), jitteriness (&le;2%), shakiness (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Dermatitis (&le;2%), diaphoresis (&le;2%), pruritus (&le;2%), urticaria (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gingival hyperplasia (&le;10%), sore throat (&le;6%), abdominal cramps (&le;2%), constipation (&le;2%), diarrhea (&le;2%), flatulence (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Sexual difficulty (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle cramps (&le;8%), tremor (&le;8%), weakness (&lt;3%), joint stiffness (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (&le;6%), nasal congestion (&le;6%),  wheezing (&le;6%), chest congestion (&le;2%), dyspnea (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&le;2%), inflammation (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute generalized exanthematous pustulosis, agranulocytosis, alopecia, altered sense of smell, anemia, aplastic anemia, angina pectoris, angioedema, arthritis (with positive ANA), bezoar formation, cardiac arrhythmia, cerebral ischemia, depression, dysgeusia, epistaxis, extrapyramidal reaction, erectile dysfunction, erythema multiforme, erythromelalgia, exfoliative dermatitis, facial edema, gastroesophageal reflux disease, gastrointestinal obstruction, gastrointestinal ulcer, gynecomastia, hematuria, hepatitis (allergic), ischemia, leukopenia, malignant neoplasm of lip (Friedman 2012), memory impairment, migraine, myalgia, myoclonus, nocturia, paranoia, parotitis, periorbital edema, polyuria, purpura, skin photosensitivity, Stevens-Johnson syndrome, syncope, tachycardia, thrombocytopenia, tinnitus, toxic epidermal necrolysis, transient blindness, ventricular arrhythmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201381\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to nifedipine or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Considered contraindicated in patients with ST-elevation myocardial infarction (STEMI) (ACCF/AHA [O'Gara 2013]); avoid use (Elkayam 1990; Yancy 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe hypotension; cardiovascular shock; breast-feeding; pregnancy or women of childbearing potential. <b>Note:</b> SOGC and ACOG guidelines recommend nifedipine as a preferred agent for maternal hypertension (ACOG 2013; SOGC [Magee 2014]). Extended release only: Hypersensitivity to other dihydropyridine calcium antagonists; Kock pouch (ileostomy after proctocolectomy); moderate or severe hepatic impairment; severe gastrointestinal obstructive disorders, concomitant use with rifampicin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201364\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Angina/MI: Increased angina and/or MI have occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade. In patients with unstable angina/non-STEMI, the use of immediate-release nifedipine is not recommended except with concomitant beta-blockade (ACCF/AHA [Anderson 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. <b>The use of immediate release nifedipine (sublingually or orally) in hypertensive emergencies and urgencies is neither safe nor effective.</b> Serious adverse events (eg, death, cerebrovascular ischemia, syncope, stroke, acute myocardial infarction, and fetal distress) have been reported.<b> Immediate release nifedipine should not be used for acute blood pressure reduction.</b> Guidelines are available when immediate release nifedipine is required for acute treatment in pregnant or postpartum women (ACOG 692 2017; Magee 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral edema: The most common side effect is peripheral edema; occurs within 2 to 3 weeks of starting therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aortic stenosis: Use with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in myocardial ischemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI strictures: Alterations in GI anatomy (eg, severe GI narrowing, history of GI cancer, obstruction, bowel resection, gastric bypass, vertical banded gastroplasty) and underlying hypomotility disorders have led to bezoar formation with extended release forms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: The ACCF/AHA heart failure guidelines recommend to avoid use in patients with HF due to lack of benefit and/or worse outcomes with calcium channel blockers in general (Yancy 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Clearance of nifedipine is reduced in cirrhotic patients leading to increased systemic exposure; monitor closely for adverse effects/toxicity and consider dose adjustments.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended release formulation: Consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract (eg, severe gastrointestinal narrowing, colon cancer, obstruction, bowel resection, gastric bypass, vertical banded gastroplasty) has been associated with symptoms of obstruction (pharmacobezoar).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immediate release formulation: Immediate release formulations should not be used to manage primary hypertension, adequate studies to evaluate outcomes have not been conducted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Adalat CC tablets contain lactose; do not use with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption syndromes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: Use with caution before major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia may result in severe hypotension and/or increased fluid requirements. Consider withdrawing nifedipine (&gt;36 hours) before surgery if possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Abrupt withdrawal may cause rebound angina in patients with CAD.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201443\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2, CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201369\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9700&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May increase the serum concentration of NIFEdipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.<b> Exceptions: </b>Fluconazole; Isavuconazonium Sulfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: NIFEdipine may enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: May increase the serum concentration of NIFEdipine. Reported with sustained release nifedipine product.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of NIFEdipine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: NIFEdipine may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FLUoxetine: May enhance the adverse/toxic effect of NIFEdipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of NIFEdipine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide.  Felodipine Canadian labeling specifically recommends avoiding its use in combination with clarithromycin.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nafcillin: May decrease the serum concentration of NIFEdipine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: NIFEdipine may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of NIFEdipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine. QuiNIDine may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some US and Canadian calcium channel blockers contraindicate use with rifampin, however recommendations vary. Consult appropriate labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of NIFEdipine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine: NIFEdipine may increase the serum concentration of VinCRIStine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): NIFEdipine may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201395\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Nifedipine serum levels may be decreased if taken with food. Food may decrease the rate but not the extent of absorption of Procardia XL. Increased nifedipine concentrations resulting in therapeutic and vasodilator side effects, including severe hypotension and myocardial ischemia, may occur if nifedipine is taken by patients ingesting grapefruit. Management: Avoid grapefruit/grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201370\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201385\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies. Nifedipine crosses the placenta (Manninen 1991; Silberschmidt 2008). An increase in perinatal asphyxia, cesarean delivery, prematurity, and intrauterine growth retardation have been reported following maternal use.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated chronic maternal hypertension is also associated with adverse events in the fetus, infant, and mother. If treatment for chronic hypertension during pregnancy is needed, nifedipine is one of the preferred agents (ACOG 2013; SOGC [Magee 2014]). Nifedipine is also recommended for the management of acute onset, severe hypertension (systolic BP &ge;160 mm Hg or diastolic BP &ge;110 mm Hg) with preeclampsia or eclampsia in pregnant and postpartum women (ACOG 692 2017; Magee 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Nifedipine has also been evaluated for the treatment of preterm labor. Tocolytics may be used for the short-term (48 hour) prolongation of pregnancy to allow for the administration of antenatal steroids and should not be used prior to fetal viability or when the risks of use to the fetus or mother are greater than the risk of preterm birth (ACOG 171 2016). Nifedipine is ineffective for maintenance tocolytic therapy (ACOG 171 2016; Roos 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21123179\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nifedipine is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The relative infant dose (RID) of nifedipine is 0.27% to 3.2% when calculated using the highest breast milk concentration located and compared to an infant therapeutic dose of 0.25 to 3 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000). Using the highest milk concentration (53.35 ng/mL), the estimated daily infant dose via breast milk is 8 mcg/kg/day. This milk concentration was obtained following maternal administration of oral nifedipine 30 mg three times daily (Ehrenkrantz 1989).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Milk concentrations reached a peak within 1 hour of maternal administration of immediate release capsules (Ehrenkrantz 1989; Penny 1989). The half-life of nifedipine in breast milk has been reported to be ~3 hours (Ehrenkrantz 1989).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The use of nifedipine in breastfeeding women for the treatment of Raynaud phenomenon has been described in case reports and case series; no adverse events were noted in the infants exposed to nifedipine via breast milk (Anderson 2004; Barrett 2013; Garrison 2002; Page 2006; Wu 2012). According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The Academy of Breastfeeding Medicine recommends the use of nifedipine for the treatment of Raynaud phenomenon of the nipple in breastfeeding mothers (Berens 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201387\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid grapefruit juice with all products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Capsule is rapidly absorbed orally if it is administered without food, but may result in vasodilator side effects; if flushing is problematic, administration with low-fat meals may decrease. In general, can take with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Adalat CC, Afeditab CR, Nifediac CC: Take on an empty stomach (manufacturer's labeling). Other extended release products may not have this recommendation; consult product labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201372\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, blood pressure, signs and symptoms of CHF, peripheral edema</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50404229\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension: </b>The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC 8]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;60 years: Goal of therapy is SBP &lt;150 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &lt;60 years: Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 years with diabetes: Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 years with chronic kidney disease (CKD): Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes and hypertension: </b>The American Diabetes Association (ADA) guidelines (ADA 2017a; ADA 2017b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 to &le;65 years: Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 to &le;65 years <b>and</b> at high risk of cardiovascular disease: Goal of therapy is SBP &lt;130 mm Hg and DBP &lt;80 mm Hg (if can be achieved without undue treatment burden).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;65 years (healthy <b>or </b>complex/intermediate health): Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;65 years (very complex/poor health): Goal of therapy is SBP &lt;150 mm Hg and DBP &lt;90 mm Hg.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201363\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina; also reduces peripheral vascular resistance, producing a reduction in arterial blood pressure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201380\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Immediate release: ~20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding (concentration dependent): 92% to 98%; <b>Note:</b> Protein-binding may be significantly decreased in patients with renal or hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4 to inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Capsule: 40% to 77%; ER: 65% to 89% relative to immediate release capsules; bioavailability increased with significant hepatic disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Adults: Healthy: 2 to 5 hours; Cirrhosis: 7 hours; Elderly: 7 hours (extended release tablet)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (60% to 80% as inactive metabolites); feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201384\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (NIFEdipine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $106.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $230.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Procardia Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $329.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Adalat CC Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $213.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $358.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (100): $419.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Afeditab CR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $125.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $224.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (NIFEdipine ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $139.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $248.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (100): $302.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (NIFEdipine ER Osmotic Release Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $132.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $229.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (100): $256.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Procardia XL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $743.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $1,286.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (100): $1,484.72</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201388\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adalat (AE, AR, AT, BE, BF, BH, BJ, BR, CH, CI, CL, CR, CZ, DE, DK, DO, EE, EG, ES, ET, FI, GB, GH, GM, GN, GR, GT, HK, HN, HR, HU, ID, IE, IT, JO, JP, KE, KR, KW, LR, LU, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NO, PA, PE, PH, PK, PL, PT, QA, RU, SA, SC, SD, SE, SL, SN, SV, TN, TR, TZ, UA, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Adalat 10 (AU);</li>\n      <li>Adalat 20 (AU);</li>\n      <li>Adalat CC (BB);</li>\n      <li>Adalat CR (BG, CH, CY, GR, JP, RO, TH);</li>\n      <li>Adalat Crono (IT);</li>\n      <li>Adalat GITS (CN, HK);</li>\n      <li>Adalat GITS 30 (PH);</li>\n      <li>Adalat L (JP);</li>\n      <li>Adalat LA (BH, ET, GB, KW, LB, MT, MY, SG);</li>\n      <li>Adalat LP (FR);</li>\n      <li>Adalat Oros (AU, BM, BR, BS, BZ, CL, CO, DK, EC, EE, ES, FI, GY, ID, IS, JM, KR, LU, NL, NO, NZ, PE, PR, PY, SE, SI, SR, TT, TW, UY, VE);</li>\n      <li>Adalat Retard (AE, AT, BF, BH, BJ, CI, CL, CR, CZ, DE, EG, ES, ET, GB, GH, GM, GN, GR, GT, HK, HN, ID, IQ, IR, JO, KE, KW, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, OM, PA, PE, PH, PL, PY, QA, SA, SC, SD, SL, SN, SV, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Adalate (FR);</li>\n      <li>Addos XR (AU);</li>\n      <li>Adefin (AU);</li>\n      <li>Adefin XL (AU);</li>\n      <li>Adifen SR (MY);</li>\n      <li>Adipine XL (GB);</li>\n      <li>Alonix-S (TW);</li>\n      <li>Altapres (PH);</li>\n      <li>Ampine (BD);</li>\n      <li>Aprical (DE, LU);</li>\n      <li>Atanaal Softcap (TW);</li>\n      <li>Calcibloc (PH);</li>\n      <li>Calcibloc OD (PH);</li>\n      <li>Calcicor (ET);</li>\n      <li>Calcigard (IN, SG, TH);</li>\n      <li>Calcigard Retard (ZW);</li>\n      <li>Cardifen (ZA);</li>\n      <li>Cardiiopine (AE);</li>\n      <li>Chronadalate LP (FR);</li>\n      <li>Citilat (IT);</li>\n      <li>Coracten (AE, BH, CY, DE, EG, GB, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Coral (IT);</li>\n      <li>Cordaflex (BG, HU, VN);</li>\n      <li>Cordilat (MX);</li>\n      <li>Cordipen (SG);</li>\n      <li>Cordipen Retard (SG);</li>\n      <li>Cordipin (HK, HR);</li>\n      <li>Cordipin Retard (HR);</li>\n      <li>Cordipin XL (HR, LV);</li>\n      <li>Corinfar (HU, LV);</li>\n      <li>Corinfar Retard (LV);</li>\n      <li>Corotrend (DE);</li>\n      <li>Depin (IN);</li>\n      <li>Depin-E Retard (TH);</li>\n      <li>Dignokonstant (DE);</li>\n      <li>Dipinkor (ID);</li>\n      <li>Duranifin (DE);</li>\n      <li>Ecodipin (CH);</li>\n      <li>Epilat (QA);</li>\n      <li>Fenamon (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Glopir (GR);</li>\n      <li>Hexadilat (DK);</li>\n      <li>Huma-Nifedin (HU);</li>\n      <li>Jutadilat (DE);</li>\n      <li>Kin Ran (CN);</li>\n      <li>Kordypin (UA);</li>\n      <li>Kordypin XL (UA);</li>\n      <li>Myogard (AE, BH, CY, EG, IN, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Nedipin (TW);</li>\n      <li>Nelapine (PH);</li>\n      <li>Nepin SR (LK);</li>\n      <li>Nicardia (TH);</li>\n      <li>Nicardia CD (TH);</li>\n      <li>Nicardia Retard (TH);</li>\n      <li>Nicardia XL (LK);</li>\n      <li>Nidipin (HU);</li>\n      <li>Nifa (BD);</li>\n      <li>Nifadil (HR);</li>\n      <li>Nifangin (FI);</li>\n      <li>Nifar (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Nifar-GB (MX);</li>\n      <li>Nifdemin (FI);</li>\n      <li>Nifebene (AT);</li>\n      <li>Nifecap (BD);</li>\n      <li>Nifecard (AE, AT, BH, HR, JO, SA);</li>\n      <li>Nifecard XL (SG);</li>\n      <li>Nifecor (DE);</li>\n      <li>Nifedepat (DE);</li>\n      <li>Nifedicor (IT);</li>\n      <li>Nifedigel (MX);</li>\n      <li>NIfedilat (ZA);</li>\n      <li>Nifedilong (IL);</li>\n      <li>Nifedin (IT);</li>\n      <li>Nifedine (IN);</li>\n      <li>Nifedipin (HR);</li>\n      <li>Nifedipin AL (HU);</li>\n      <li>Nifedipin Pharmavit (HU);</li>\n      <li>Nifedipin Stada (LU);</li>\n      <li>Nifedipin-ratiopharm (LU);</li>\n      <li>Nifedipresc MR (GB);</li>\n      <li>Nifedix SR (KR);</li>\n      <li>Nifehexal (LU, VN);</li>\n      <li>Nifelan (EC);</li>\n      <li>Nifelat (AR, ET, HK, MT, SG, TH, ZW);</li>\n      <li>Nifelat Q (TR);</li>\n      <li>Nifelat R (ZW);</li>\n      <li>Nifelat-Q (TH);</li>\n      <li>Nifensar (PE);</li>\n      <li>Nifensar Retard (PE);</li>\n      <li>Niferon CR (KR);</li>\n      <li>Nifeslow (LU);</li>\n      <li>Nifestad (PH);</li>\n      <li>Nifezzard (MX);</li>\n      <li>Nificard (CY, EG, IQ, IR, KW, LB, LY, OM, QA, SY, YE);</li>\n      <li>Nifin (BD);</li>\n      <li>Nifipen (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Nipen (BD);</li>\n      <li>Noviken LP (MX);</li>\n      <li>Nyefax (AU);</li>\n      <li>Nyefax Retard (NZ);</li>\n      <li>Odipin (PH);</li>\n      <li>Orix (GR);</li>\n      <li>Osmo-Adalat (IL);</li>\n      <li>Pidilat (DE);</li>\n      <li>Pressolat (IL);</li>\n      <li>Sepamit (JP);</li>\n      <li>Servidipine (MY);</li>\n      <li>Slow-Nifine (LU);</li>\n      <li>Unidipin (HU, LU);</li>\n      <li>Zenusin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adalat CC (nifedipine extended release tablet) [prescribing information]. Pine Brook, NJ: Almatica Pharma Inc.; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adalat XL (nifedipine extended release tablet) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc.; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28333820\"></a>American College of Obstetricians and Gynecologists (ACOG). Committee on Obstetric Practice. Committee Opinion No. 692: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period. <i>Obstet Gynecol.</i> 2017;129(4):e90-e95. doi: 10.1097/AOG.0000000000002019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/28333820/pubmed\" target=\"_blank\" id=\"28333820\">28333820</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26695585\"></a>American College Of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 171: Management of Preterm Labor. <i>Obstet Gynecol</i>. 2016;128(4):e155-e164. doi: 10.1097/AOG.0000000000001711.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/27661654/pubmed\" target=\"_blank\" id=\"27661654\">27661654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG); Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/24150027/pubmed\" target=\"_blank\" id=\"24150027\">24150027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979896\"></a>American Diabetes Association (ADA). 9. Cardiovascular disease and risk management. <i>Diabetes Care. </i>2017a;40(suppl 1):S75-S87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/27979896/pubmed\" target=\"_blank\" id=\"27979896\">27979896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979898\"></a>American Diabetes Association (ADA). 11. Older adults. <i>Diabetes Care</i>. 2017b;40(suppl 1):S99&ndash;S104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/27979898/pubmed\" target=\"_blank\" id=\"27979898\">27979898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JE, Held N, Wright K. Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding. <i>Pediatrics</i>. 2004;113(4):e360-364.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/15060268/pubmed\" target=\"_blank\" id=\"15060268\">15060268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JL, Adams CD, Antman EM, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(23):e663-e828. doi: 10.1161/CIR.0b013e31828478ac.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/23630129/pubmed\" target=\"_blank\" id=\"23630129\">23630129</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>Circulation</i>, 2011, 123(21):2434-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/21518977/pubmed\" target=\"_blank\" id=\"21518977\">21518977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23682366\"></a>Barrett ME, Heller MM, Stone HF, et al, &quot;Raynaud Phenomenon of the Nipple in Breastfeeding Mothers: An Underdiagnosed Cause of Nipple Pain,&quot; <i>JAMA Dermatol</i>, 2013, 149(3):300-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/23682366/pubmed\" target=\"_blank\" id=\"23682366\">23682366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1922223\"></a>B&auml;rtsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O. Prevention of high-altitude pulmonary edema by nifedipine. <i>N Engl J Med</i>. 1991;325(18):1284-1289.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/1922223/pubmed\" target=\"_blank\" id=\"1922223\">1922223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26881962\"></a>Berens P, Eglash A, Malloy M, Steube AM. ABM clinical protocol #26: persistent pain with breastfeeding. <i>Breastfeed Med</i>. 2016;11(2):46-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/26881962/pubmed\" target=\"_blank\" id=\"26881962\">26881962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deen-Duggins L, Fry HR, Clay JR, et al, &ldquo;Nifedipine-Associated Gingival Overgrowth: A Survey of the Literature and Report of Four Cases,&rdquo; <i>Quintessence Int</i>, 1996, 27(3):163-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/9063228 /pubmed\" target=\"_blank\" id=\"9063228 \">9063228 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22441082\"></a>Deshwal R, Iqbal M, Basnet S. Nifedipine for the treatment of high altitude pulmonary edema. <i>Wilderness Environ Med</i>. 2012;23(1):7-10. doi:10.1016/j.wem.2011.10.003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/22441082/pubmed\" target=\"_blank\" id=\"22441082\">22441082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ehrenkranz RA, Ackerman BA, and Hulse JD, &quot;Nifedipine Transfer Into Human Milk,&quot; <i>J Pediatr</i>, 1989, 114(3):478-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/2921695/pubmed\" target=\"_blank\" id=\"2921695\">2921695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2242521\"></a>Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. <i>Circulation</i>. 1990;82(6):1954-1961.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/2242521/pubmed\" target=\"_blank\" id=\"2242521\">2242521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedman GD, Asgari MM, Warton EM, et al, &quot;Antihypertensive Drugs and Lip Cancer in Non-Hispanic Whites,&quot; <i>Arch Intern Med</i>, 2012, 6:1-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/22869299/pubmed\" target=\"_blank\" id=\"22869299\">22869299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furberg Cd, Psaty BM, and Meyer JV, &ldquo;Nifedipine: Dose-Related Increase in Mortality in Patients With Coronary Heart Disease,&rdquo; <i>Circulation</i>, 1995, 92(5):1326-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/7648682/pubmed\" target=\"_blank\" id=\"7648682\">7648682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gali&egrave; N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). <i>Eur Heart J</i>. 2016;37(1):67-119. doi:10.1093/eurheartj/ehv317.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/15589643/pubmed\" target=\"_blank\" id=\"15589643\">15589643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garrison CP. Nipple vasospasms, Raynaud's syndrome, and nifedipine. <i>J Hum Lact</i>. 2002;18(4):382-385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/12449056/pubmed\" target=\"_blank\" id=\"12449056\">12449056</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22315243\"></a>Goundry B, Bell L, Langtree M, et al, &quot;Diagnosis and Management of Raynaud's Phenomenon,&quot; <i>BMJ</i>, 2012, 344:e289.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/22315243/pubmed\" target=\"_blank\" id=\"22315243\">22315243</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grossman E, Messerli FH, Grodzicki T, et al, &ldquo;Should a Moratorium Be Placed on Sublingual Nifedipine Capsules Given for Hypertensive Emergencies and Pseudoemergencies?&rdquo; <i>JAMA</i>, 1996, 276(16):1328-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/8861992/pubmed\" target=\"_blank\" id=\"8861992\">8861992</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harel-Raviv M, Eckler M, Lalani K, et al, &ldquo;Nifedipine-Induced Gingival Hyperplasia. A Comprehensive Review and Analysis,&rdquo; <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i>, 1995, 79(6):715-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/7621029 /pubmed\" target=\"_blank\" id=\"7621029 \">7621029 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ishikawa K, Nakai S, Takenaka T, et al, &ldquo;Short-Acting Nifedipine and Diltiazem Do Not Reduce the Incidence of Cardiac Events in Patients With Healed Myocardial Infarction. Secondary Prevention Group,&rdquo; <i>Circulation</i>, 1997, 95(10):2368-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/9170398/pubmed\" target=\"_blank\" id=\"9170398\">9170398</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. <i>JAMA</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luks AM, McIntosh SE, Grissom CK, et al; Wilderness Medical Society. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. <i>Wilderness Environ Med</i>. 2014;25(4 suppl):S4-S14. doi:10.1016/j.wem.2014.06.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/25498261/pubmed\" target=\"_blank\" id=\"25498261\">25498261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magee LA, Pels A, Helewa M, et al; Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. <i>J Obstet Gynaecol Can</i>. 2014;36(5):416-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/24927294/pubmed\" target=\"_blank\" id=\"24927294\">24927294</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manninen AK and Juhakoski A, &quot;Nifedipine Concentrations in Maternal and Umbilical Serum, Amniotic Fluid, Breast Milk and Urine of Mothers and Offspring,&quot; <i>Int J Clin Pharmacol Res</i>, 1991, 11(5):231-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/1814844/pubmed\" target=\"_blank\" id=\"1814844\">1814844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Messerli FH, Kowey P, and Grodzicki T, &ldquo;Sublingual Nifedipine for Hypertensive Emergencies,&rdquo; <i>Lancet</i>, 1991, 338(8771):881.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/1681227/pubmed\" target=\"_blank\" id=\"1681227\">1681227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo; <i>Pediatrics</i>, 2004, 114(2 Suppl):555-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nery EB, Edson RG, Lee KK, et al, &ldquo;Prevalence of Nifedipine-Induced Gingival Hyperplasia,&rdquo; <i>J Periodontol</i>, 1995, 66(7):572-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/7562349 /pubmed\" target=\"_blank\" id=\"7562349 \">7562349 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nifedipine [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; June 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishikawa SJ, Tada H, Hamasaki A, et al, &ldquo;Nifedipine-Induced Gingival Hyperplasia: A Clinical and In Vitro Study,&rdquo; <i>J Periodontol</i>, 1991, 62(1):30-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/2002429 /pubmed\" target=\"_blank\" id=\"2002429 \">2002429 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1483797\"></a>Oelz O, Maggiorini M, Ritter M, et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. <i>Int J Sports Med</i>. 1992;13(suppl 1):S65-S68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/1483797/pubmed\" target=\"_blank\" id=\"1483797\">1483797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17018510\"></a>Page SM, McKenna DS. Vasospasm of the nipple presenting as painful lactation. <i>Obstet Gynecol</i>. 2006;108(3 Pt 2):806-808.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/17018510/pubmed\" target=\"_blank\" id=\"17018510\">17018510</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Penny WJ and Lewis MJ, &quot;Nifedipine Is Excreted in Human Milk,&quot; <i>Eur J Clin Pharmacol</i>, 1989, 36(4):427-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/2737237/pubmed\" target=\"_blank\" id=\"2737237\">2737237</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pollard AJ, Niermeyer S, Barry P, et al, &ldquo;Children at High Altitude: An International Consensus Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001,&rdquo; <i>High Alt Med Biol</i>, 2001, 2(3):389-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/11682018/pubmed\" target=\"_blank\" id=\"11682018\">11682018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poole-Wilson PA, Lubsen J, Kirwan BA, et al, &ldquo;Effect of Long-Acting Nifedipine on Mortality and Cardiovascular Morbidity in Patients with Stable Angina Requiring Treatment (Action Trial): Randomized Controlled Trial,&rdquo; <i>Lancet</i>, 2004, 364(9437):849-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/15351192/pubmed\" target=\"_blank\" id=\"15351192\">15351192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prisant LM and Spaulding VC, &ldquo;Antihypertensive Pharmacobezoar,&rdquo; <i>J Clin Hypertens (Greenwich)</i>, 2006, 8(4):296-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/16596036/pubmed\" target=\"_blank\" id=\"16596036\">16596036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Procardia (nifedipine) [prescribing information]. New York, NY: Pfizer; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Procardia XL (nifedipine) [prescribing information]. New York, NY: Pfizer; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Psaty BM, Heckbert SR, Koepsell TD, et al, &ldquo;The Risk of Myocardial Infarction Associated With Antihypertensive Therapies,&rdquo; <i>JAMA</i>, 1995, 274(8):620-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/7637142/pubmed\" target=\"_blank\" id=\"7637142\">7637142</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10789602\"></a>Raynaud's Treatment Study Investigators. Comparison of Sustained-Release Nifedipine and Temperature Biofeedback for Treatment of Primary Raynaud Phenomenon. Results From a Randomized Clinical Trial With 1-Year Follow-Up. <i>Arch Intern Med</i>, 2000, 160(8):1101-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/10789602/pubmed\" target=\"_blank\" id=\"10789602\">10789602</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1603139\"></a>Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. <i>N Engl J Med</i>. 1992;327(2):76-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/1603139/pubmed\" target=\"_blank\" id=\"1603139\">1603139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roos C, Spaanderman ME, Schuit E, et al, &quot;Effect of Maintenance Tocolysis With Nifedipine in Threatened Preterm Labor on Perinatal Outcomes: a Randomized Controlled Trial,&quot; <i>JAMA</i>, 2013, 309(1):41-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/23280223/pubmed\" target=\"_blank\" id=\"23280223\">23280223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scognamiglio R, Rahimtoola SH, Fasoli G, et al, &ldquo;Nifedipine in Asymptomatic Patients With Severe Aortic Regurgitation and Normal Left Ventricular Function,&rdquo; <i>N Engl J Med</i>, 1994, 331(11):689-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/8058074/pubmed\" target=\"_blank\" id=\"8058074\">8058074</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scorza R, Caronni M, Mascagni B, et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. <i>Clin Exp Rheumatol</i>. 2001;19(5):503-508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/11579708/pubmed\" target=\"_blank\" id=\"11579708\">11579708</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silberschmidt AL, Kuhn-Velten WN, Juon AM, et al, &ldquo;Nifedipine Concentration in Maternal and Umbilical Cord Blood After Nifedipine Gastrointestinal Therapeutic System for Tocolysis,&rdquo; <i>BJOG</i>, 2008, 115(4):480-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/18271884 /pubmed\" target=\"_blank\" id=\"18271884 \">18271884 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silverstein LH, Koch JP, Lefkove MD, et al, &ldquo;Nifedipine-Induced Gingival Enlargement Around Dental Implants: A Clinical Report,&rdquo; <i>J Oral Implantol</i>, 1995, 21(2):116-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/8699502 /pubmed\" target=\"_blank\" id=\"8699502 \">8699502 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sitbon O, Humbert M, Jais X, et al, &ldquo;Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension,&rdquo; <i>Circulation</i>, 2005, 111(23):3105-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/15939821/pubmed\" target=\"_blank\" id=\"15939821\">15939821</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steele RM, Schuna AA, and Schreiber RT, &ldquo;Calcium Antagonist-Induced Gingival Hyperplasia,&rdquo; <i>Ann Intern Med</i>, 1994, 120(8):663-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/8135450/pubmed\" target=\"_blank\" id=\"8135450\">8135450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <i>Chest</i>. 2014;146(2):449-475. doi:10.1378/chest.14-0793.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/24937180/pubmed\" target=\"_blank\" id=\"24937180\">24937180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. <i>Rheumatology (Oxford)</i>. 2005;44(2):145-150.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/15546967/pubmed\" target=\"_blank\" id=\"15546967\">15546967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23877351\"></a>Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. <i>Am J Gastroenterol</i>. 2013;108(8):1238-1249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/23877351/pubmed\" target=\"_blank\" id=\"23877351\">23877351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26. doi: 10.1111/jch.12237.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Westbrook P, Bednarczyk EM, Carlson M, et al, &ldquo;Regression of Nifedipine-Induced Gingival Hyperplasia Following Switch to a Same Class Calcium Channel Blocker, Isradipine,&rdquo; <i>J Periodontol</i>, 1997, 68(7):645-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/9249636 /pubmed\" target=\"_blank\" id=\"9249636 \">9249636 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11247310\"></a>Wigley FM, &ldquo;Clinical Practice. Raynaud&rsquo;s Phenomenon,&rdquo; <i>N Engl J Med</i>, 2002, 347(13):1001-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/11247310/pubmed\" target=\"_blank\" id=\"11247310\">11247310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22270434\"></a>Wu M, Chason R, and Wong M, &quot;Raynaud's Phenomenon of the Nipple,&quot; <i>Obstet Gynecol</i>, 2012, 119(2 Pt 2):447-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/22270434/pubmed\" target=\"_blank\" id=\"22270434\">22270434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &quot;Calcium Channel Blockers and Gingival Hyperplasia-An Update,&quot; <i>Gen Dent</i>, 2009, 57(2):105-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/19552357/pubmed\" target=\"_blank\" id=\"19552357\">19552357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21083640\"></a>Ye Z, Yang H, Li H, et al. A multicentre, prospective, randomized trial: comparative efficacy of tamsulosin and nifedipine in medical expulsive therapy for distal ureteric stones with renal colic. <i>BJU Int</i>. 2011;108(2):276-279.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/21083640/pubmed\" target=\"_blank\" id=\"21083640\">21083640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhang MY, Ding ST, L&uuml; JJ, et al. Comparison of tamsulosin with extracorporeal shock wave lithotripsy in treating distal ureteral stones. <i>Chin Med J (Engl)</i>. 2009;122(7):798-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-drug-information/abstract-text/19493392/pubmed\" target=\"_blank\" id=\"19493392\">19493392</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9700 Version 257.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F201399\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F201400\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F201448\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F201404\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F201425\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F201405\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F10293332\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F201406\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F201374\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F201360\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F201378\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F201377\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469158\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F201456\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F201367\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F201381\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F201364\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F201443\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F201369\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F201395\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F201370\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F201385\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21123179\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F201387\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F201372\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F50404229\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F201363\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F201380\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F201384\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F201388\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9700|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nifedipine-patient-drug-information\" class=\"drug drug_patient\">Nifedipine: Patient drug information</a></li><li><a href=\"topic.htm?path=nifedipine-pediatric-drug-information\" class=\"drug drug_pediatric\">Nifedipine: Pediatric drug information</a></li></ul></div></div>","javascript":null}